Philip Home
Philip Home
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study [0.03%]
一周一次的基础胰岛素Fc治疗2型糖尿病患者的疗效和安全性：一项多中心、开放标签、随机II期研究
Juan Frias,Jenny Chien,Qianyi Zhang et al.
Juan Frias et al.
Background: The burden of daily basal insulins often causes hesitancy and delays in the initiation of insulin therapy. Basal insulin Fc (BIF, insulin efsitora alfa), designed for once-weekly administration, is a fusion pr...
Laura C Kusinski,Claire L Meek
Laura C Kusinski
Sylvia Kehlenbrink,Kiran Jobanputra;International Alliance for Diabetes Action
Sylvia Kehlenbrink
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial [0.03%]
母亲妊娠期2型糖尿病使用二甲双胍与安慰剂对子代结局的影响：MiTy随机对照试验的24个月随访（MiTy Kids）
Denice S Feig,J Johanna Sanchez,Kellie E Murphy et al.
Denice S Feig et al.
Background: Metformin is increasingly being used during pregnancy, with potentially adverse long-term effects on children. We aimed to examine adiposity in children of women with type 2 diabetes from the Metformin in Wome...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2023 Mar;11(3):191-202. DOI:10.1016/S2213-8587(23)00004-9 2023
Implications of technology guidelines for low-income and middle-income countries [0.03%]
技术指南对中低收入国家的影响
Yashdeep Gupta,Alpesh Goyal,Nikhil Tandon
Yashdeep Gupta
David Beran,Kurt Højlund,Stéphane Besançon et al.
David Beran et al.
Sten Madsbad
Sten Madsbad
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial [0.03%]
钠葡萄糖协同转运蛋白2抑制剂恩格列净与安慰剂及二肽基肽酶4抑制剂利格列汀与安慰剂在2型糖尿病青年患者中的疗效和安全性比较：一项多中心、随机、双盲、平行分组、III期临床试验（DINAMO研究）
Lori M Laffel,Thomas Danne,Georgeanna J Klingensmith et al.
Lori M Laffel et al.
Background: The incidence of type 2 diabetes in young people is increasing, but treatments remain limited. We aimed to assess the efficacy and safety of an empagliflozin dosing regimen versus placebo and linagliptin versu...
Talha Burki
Talha Burki